title: Adolescent Clinical Development of Ezogabine/Retigabine as Adjunctive Therapy for Partial-Onset Seizures: Pharmacokinetics and Tolerability.
abstract: OBJECTIVES:To explore the pharmacokinetic (PK) profile and safety of ezogabine (EZG)/retigabine (RTG) as adjunctive therapy for uncontrolled partial-onset seizures (POS) in adolescents.METHODS:In this multiple-dose study (NCT01494584), adolescents with POS received EZG/RTG immediate-release tablets three times daily (TID) as adjunctive therapy to 1 to 3 concurrent antiepileptic drugs. The study comprised a screening phase, and a 5- to 8-week treatment phase starting with 100 mg TID up-titrated once weekly by ≤50 mg TID to a maximum dosage of 300 mg TID. There were 8 venous blood samples and 2 finger-prick blood samples collected for PK analysis during 8-hour time periods at the target dosages of 100, 200, and 300 mg TID.RESULTS:This study was terminated prematurely on US Food and Drug Administration advice due to pigmentation/discoloration findings in long-term, open-label extension studies in adults. Five participants (ages 13-16 years) had enrolled in the study. For the EZG/RTG 100-, 200-, and 300-mg doses, the area under the concentration-time curve during the dosage intervals was 1680, 2559, and 3784 ng/hr/mL; maximum plasma concentrations were 370, 536, and 751 ng/mL, and minimum plasma concentrations were 105, 200, and 287 ng/mL, respectively. Venous and finger-prick concentrations of EZG/RTG were similar. No significant adverse events were observed during treatment (133-213 days).CONCLUSIONS:EZG/RTG PK appeared linear across the dosage range of 100 to 300 mg TID in adolescents with POS, and were consistent with adult observations. The small sample size and short study duration preclude conclusions regarding the safety and efficacy of EZG/RTG.
authors.affiliation: GlaxoSmithKline, Stevenage, United Kingdom.
authors.forename: Debra J
authors.initials: DJ
authors.lastname: Tompson
authors.affiliation: GlaxoSmithKline, Stevenage, United Kingdom.
authors.forename: Mauro
authors.initials: M
authors.lastname: Buraglio
authors.affiliation: GlaxoSmithKline, Research Triangle Park, North Carolina.
authors.forename: Susan M
authors.initials: SM
authors.lastname: Andrews
authors.affiliation: Pediatric Neurology, University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis, Tennessee.
authors.forename: James W
authors.initials: JW
authors.lastname: Wheless
keywords: adolescent; anticonvulsant; antiepileptic drug; epilepsy; ezogabine; pharmacokinetics; retigabine; seizures